Stéphane P Poulin1,2, David Bergeron1, Bradford C Dickerson3,4,5,6,7. 1. Clinique Interdisciplinaire de la Mémoire, Centre Hositalier Universitaire de Québec, Quebec City, QC, Canada. 2. Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec (CRISUMQ), QC, Canada. 3. Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. 4. Department of Psychiatry, Massachusetts General Hospital, Charlestown, MA, USA. 5. Department of Frontotemporal Dementia Unit, Massachusetts General Hospital, Charlestown, MA, USA. 6. Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Charlestown, MA, USA. 7. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Abstract
BACKGROUND: An integrative model of neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) is lacking. OBJECTIVE: In this study, we investigated the risk factors, anatomy, biology, and outcomes of NPS in AD. METHODS: 181 subjects were included from the Alzheimer's Disease Neuroimaging Study (ADNI). NPS were assessed with the Neuropsychiatric Inventory Questionnaire at baseline and 6 months. NPI >3 was used as a threshold for NPS positivity. Three NPS courses were characterized: 1) minimal/absent (negative at 0 and 6 months, n = 77); 2) fluctuating (positive only at one time point, n = 53); 3) persistent (positive at both time points, n = 51). We examined the association between NPS course and family history of dementia, personal history of psychiatric disorders, cerebrospinal fluid biomarkers, atrophy patterns, as well as longitudinal cognitive and functional measures at 12 and 24 months (MMSE, CDR-SOB, FAQ). RESULTS: AD subjects with absent, fluctuating, or persistent NPS had similar CSF amyloid-β and tau levels. AD subjects with minimal/absent NPS had less personal history of psychiatric disorders (35%) than those with fluctuating (57%; p = 0.015) or persistent NPS (47%, not significant). At 24 months, AD subjects with persistent NPS had worse cognitive (MMSE; p = 0.05) and functional (CDR-SOB; p = 0.016) outcomes. Dorsolateral prefrontal atrophy was seen in persistent NPS, but not in fluctuating NPS. CONCLUSIONS: Our results suggest that individuals with personal history of psychiatric disorders might be more vulnerable to develop NPS throughout the course of AD. The worst cognitive and functional outcomes associated with NPS in AD underscores the importance of monitoring NPS early in the disease course.
BACKGROUND: An integrative model of neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) is lacking. OBJECTIVE: In this study, we investigated the risk factors, anatomy, biology, and outcomes of NPS in AD. METHODS: 181 subjects were included from the Alzheimer's Disease Neuroimaging Study (ADNI). NPS were assessed with the Neuropsychiatric Inventory Questionnaire at baseline and 6 months. NPI >3 was used as a threshold for NPS positivity. Three NPS courses were characterized: 1) minimal/absent (negative at 0 and 6 months, n = 77); 2) fluctuating (positive only at one time point, n = 53); 3) persistent (positive at both time points, n = 51). We examined the association between NPS course and family history of dementia, personal history of psychiatric disorders, cerebrospinal fluid biomarkers, atrophy patterns, as well as longitudinal cognitive and functional measures at 12 and 24 months (MMSE, CDR-SOB, FAQ). RESULTS:AD subjects with absent, fluctuating, or persistent NPS had similar CSF amyloid-β and tau levels. AD subjects with minimal/absent NPS had less personal history of psychiatric disorders (35%) than those with fluctuating (57%; p = 0.015) or persistent NPS (47%, not significant). At 24 months, AD subjects with persistent NPS had worse cognitive (MMSE; p = 0.05) and functional (CDR-SOB; p = 0.016) outcomes. Dorsolateral prefrontal atrophy was seen in persistent NPS, but not in fluctuating NPS. CONCLUSIONS: Our results suggest that individuals with personal history of psychiatric disorders might be more vulnerable to develop NPS throughout the course of AD. The worst cognitive and functional outcomes associated with NPS in AD underscores the importance of monitoring NPS early in the disease course.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: Giacomo Salvadore; Allison C Nugent; Herve Lemaitre; David A Luckenbaugh; Ruth Tinsley; Dara M Cannon; Alexander Neumeister; Carlos A Zarate; Wayne C Drevets Journal: Neuroimage Date: 2010-11-10 Impact factor: 6.556
Authors: Paula T Trzepacz; Peng Yu; Phani K Bhamidipati; Brian Willis; Tammy Forrester; Linda Tabas; Adam J Schwarz; Andrew J Saykin Journal: Alzheimers Dement Date: 2012-12-17 Impact factor: 21.566
Authors: Julie S Snowden; Cheryl L Stopford; Camille L Julien; Jennifer C Thompson; Yvonne Davidson; Linda Gibbons; Antonia Pritchard; Corinne L Lendon; Anna M Richardson; Anoop Varma; David Neary; David Mann Journal: Cortex Date: 2007-10 Impact factor: 4.027
Authors: Peter V Rabins; Sarah Schwartz; Betty S Black; Christopher Corcoran; Elizabeth Fauth; Michele Mielke; Jessica Christensen; Constantine Lyketsos; Joann Tschanz Journal: Alzheimers Dement Date: 2012-11-02 Impact factor: 21.566
Authors: Ross M G Norman; Rahul Manchanda; Ashok K Malla; Raj Harricharan; Sandra Northcott Journal: J Nerv Ment Dis Date: 2007-10 Impact factor: 2.254
Authors: Milap A Nowrangi; Christopher Marano; Kenichi Oishi; Susumu Mori; Haris I Sair; John Outen; Jeannie Leoutsakos; Constantine Lyketsos; Paul B Rosenberg Journal: Int Psychogeriatr Date: 2020-02-28 Impact factor: 3.878
Authors: T Möllers; L Perna; H Stocker; P Ihle; I Schubert; B Schöttker; L Frölich; J Bauer; H Brenner Journal: Epidemiol Psychiatr Sci Date: 2019-11-14 Impact factor: 6.892